It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
Elon Musk’s Neuralink has been given a green light to implant its brain chip in a second patient aft2024-05-21DAILY MAIL COMMENT: Will Rayner now tell the whole truth?
At long last, Greater Manchester Police deign to investigate allegations that Angela Rayner breached2024-05-21Inside Jon Richardson and Lucy Beaumont's 9
Jon Richardson and Lucy Beaumont have announced they are divorcing after nine years of marriage. The2024-05-21Xi Plants Trees in Beijing, Urging Nationwide Afforestation Efforts for Beautiful China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21The unstoppable duo of Emma Stone and Yorgos Lanthimos
CANNES, France (AP) — Before a journalist has even lobbed a question, Emma Stone and Yorgos Lanthimo2024-05-21Chinese books on display at Paris Book Festival 2024
A woman reads a Chinese book during Paris Book Festival 2024 in Paris, France, April 12, 2024. The b2024-05-21
atest comment